Novartis (NOVN) PT Set at CHF 92 by Morgan Stanley

Novartis (VTX:NOVN) has been assigned a CHF 92 price target by equities research analysts at Morgan Stanley in a research report issued on Friday. The firm presently has a “buy” rating on the stock. Morgan Stanley’s target price would indicate a potential upside of 10.34% from the stock’s previous close.

Several other brokerages also recently weighed in on NOVN. UBS Group set a CHF 78 target price on shares of Novartis and gave the company a “neutral” rating in a research note on Monday, October 23rd. JPMorgan Chase & Co. set a CHF 84 target price on shares of Novartis and gave the company a “neutral” rating in a research note on Wednesday, January 10th. Deutsche Bank set a CHF 83.50 target price on shares of Novartis and gave the company a “neutral” rating in a research note on Wednesday, October 4th. S&P Global set a CHF 87 target price on shares of Novartis and gave the company a “neutral” rating in a research note on Tuesday, October 24th. Finally, set a CHF 90 target price on shares of Novartis and gave the company a “buy” rating in a research note on Monday, October 30th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and seven have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of CHF 87.38.

Novartis (NOVN) traded up CHF 0.48 during trading on Friday, hitting CHF 83.38. 6,510,000 shares of the stock traded hands, compared to its average volume of 4,040,000. Novartis has a 52 week low of CHF 69.50 and a 52 week high of CHF 85.40. The firm has a market capitalization of $216,680.00 and a price-to-earnings ratio of 30.88.

TRADEMARK VIOLATION WARNING: This piece was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/19/novartis-novn-pt-set-at-chf-92-by-morgan-stanley.html.

Novartis Company Profile

Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply